Wide Ranks

ALVR

AlloVir, Inc.

0.5408

Top Statistics
Market Cap 62 M Forward PE -1.69 Revenue Growth 0.00 %
Current Ratio 55.08 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.4880 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 129 M Total Cash Per Share 1.14 Total Debt 9 M
Total Debt To Equity 7.48 Current Ratio 55.08 Book Value Per Share 1.31
All Measures
Short Ratio 2003.00 % Message Board Id finmb_383379282 Shares Short Prior Month 5 M
Return On Equity -0.8033 City Waltham Uuid 4699e226-3958-33a1-9cfb-163a3892f26e
Previous Close 0.5348 First Trade Date Epoch Utc 1 B Book Value 1.31
Beta 0.7410 Total Debt 9 M Volume 98890
Price To Book 0.4113 Fifty Two Week Low 0.5100 Total Cash Per Share 1.14
Shares Short Previous Month Date 1 B Target Median Price 1.50 Audit Risk 9
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 1.50
Net Income To Common -140343008 Short Percent Of Float 0.0634 Implied Shares Outstanding 115 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 390730
Average Volume10days 390730 Total Cash 129 M Next Fiscal Year End 1 B
Held Percent Insiders 0.4912 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 0.5348
Target Low Price 1.50 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.7575
Open 0.5448 Free Cashflow -58263876 State MA
Dividend Yield 0.00 % Return On Assets -0.3653 Time Zone Short Name EST
Board Risk 9 Trailing Eps -0.8800 Day Low 0.5150
Address1 1100 Winter Street Shares Outstanding 115 M Compensation Risk 10
Price Hint 4 Target High Price 1.50 Website https://www.allovir.com
52 Week Change -0.7122 Average Volume 303735 Forward Eps -0.3200
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 5498.40 %
Is_sp_500 False Regular Market Day High 0.5500 Profit Margins 0.00 %
Debt To Equity 7.48 Fifty Two Week High 2.48 Day High 0.5500
Shares Short 3 M Regular Market Open 0.5448 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0343
Operating Cashflow -120910000 Currency USD Time Zone Full Name America/New_York
Market Cap 62 M Is_nasdaq_100 False Zip 02451
Quote Type EQUITY Industry Biotechnology Long Name AlloVir, Inc.
Overall Risk 10 Regular Market Day Low 0.5150 Held Percent Institutions 0.4179
Current Price 0.5408 Enterprise To Ebitda 0.4880 Financial Currency USD
Current Ratio 55.08 Industry Disp Biotechnology Number Of Analyst Opinions 1
Country United States Float Shares 30 M Two Hundred Day Average 0.7566
Governance Epoch Date 1 B Enterprise Value -58813416 Forward PE -1.69
Regular Market Volume 98890 Ebitda -120465000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases.

The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.

The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019.

The company was incorporated in 2013 and is based in Waltham, Massachusetts.